Annual revenue was KRW 3.18 billion in 2022, KRW 1.93 billion in 2023 (down 39.2% year on year), KRW 10.8 billion in 2024 (up 461.1%), and KRW 7.47 billion in 2025 (down 31.1%). 2024 was the largest year and 2023 the smallest among 2022 to 2025.
Operating losses were KRW 6.16 billion, KRW 6.73 billion, KRW 10.1 billion, and KRW 10.6 billion over the same years, with operating margins of -193.6%, -348.0%, -93.1%, and -141.3%. Revenue rose sharply in 2024, and the operating margin improved from 2023, yet the operating loss in won terms widened.
Net losses attributable to controlling shareholders were KRW 5.33 billion, KRW 6.74 billion, KRW 9.08 billion, and KRW 10.7 billion, a loss every year from 2022 through 2025.
The company attributed the 2025 revenue decline to market changes in the machine vision AI end markets, and the wider loss to higher fixed costs such as personnel expenses from expanding medical AI R&D staff.
In the first half of 2025, gross profit rose about sixfold year on year, which was mainly attributed to better margins in industrial AI. The debt ratio was 45.8% in 2022, 26.7% in 2023, 67.9% in 2024, and 42.0% in 2025. Total equity rose from KRW 19 billion at the end of 2024 to KRW 28.5 billion at the end of 2025.
Operating cash flow was negative in all four years: -KRW 3.71 billion, -KRW 4.77 billion, -KRW 13.9 billion, and -KRW 6.36 billion. By quarter, revenue was KRW 2.18 billion in Q3 2025, KRW 659 million in Q4 2025, KRW 357 million in Q1 2026, KRW 1.31 billion in Q2 2026, and KRW 439 million in Q3 2026, swinging widely.
Operating losses were KRW 3.04 billion, KRW 3.72 billion, KRW 3.98 billion, KRW 3.3 billion, and KRW 3.66 billion over the same five quarters, and only Q2 2026 showed a narrower loss. Net losses attributable to controlling shareholders over the four quarters from Q4 2025 to Q3 2026 totaled KRW 15 billion.